Insights by which TUDCA is a potential therapy against adiposity

Adipose tissue is an organ with metabolic and endocrine activity. White, brown and ectopic adipose tissues have different structure, location, and function. Adipose tissue regulates energy homeostasis, providing energy in nutrient-deficient conditions and storing it in high-supply conditions. To att...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in endocrinology (Lausanne) Vol. 14; p. 1090039
Main Authors: Freitas, Israelle Netto, da Silva, Jr, Joel Alves, de Oliveira, Kênia Moreno, Lourençoni Alves, Bruna, Dos Reis Araújo, Thiago, Camporez, João Paulo, Carneiro, Everardo Magalhães, Davel, Ana Paula
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 21-02-2023
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adipose tissue is an organ with metabolic and endocrine activity. White, brown and ectopic adipose tissues have different structure, location, and function. Adipose tissue regulates energy homeostasis, providing energy in nutrient-deficient conditions and storing it in high-supply conditions. To attend to the high demand for energy storage during obesity, the adipose tissue undergoes morphological, functional and molecular changes. Endoplasmic reticulum (ER) stress has been evidenced as a molecular hallmark of metabolic disorders. In this sense, the ER stress inhibitor tauroursodeoxycholic acid (TUDCA), a bile acid conjugated to taurine with chemical chaperone activity, has emerged as a therapeutic strategy to minimize adipose tissue dysfunction and metabolic alterations associated with obesity. In this review, we highlight the effects of TUDCA and receptors TGR5 and FXR on adipose tissue in the setting of obesity. TUDCA has been demonstrated to limit metabolic disturbs associated to obesity by inhibiting ER stress, inflammation, and apoptosis in adipocytes. The beneficial effect of TUDCA on perivascular adipose tissue (PVAT) function and adiponectin release may be related to cardiovascular protection in obesity, although more studies are needed to clarify the mechanisms. Therefore, TUDCA has emerged as a potential therapeutic strategy for obesity and comorbidities.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Bruno Melo Carvalho, Universidade de Pernambuco, Brazil
This article was submitted to Obesity, a section of the journal Frontiers in Endocrinology
Reviewed by: Elisa Villalobos, Newcastle University, United Kingdom; Xavier Prieur, U1087 Institut du Thorax (INSERM), France
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2023.1090039